Literature DB >> 21447232

Orexin-1 receptor signalling within the ventral tegmental area, but not the paraventricular thalamus, is critical to regulating cue-induced reinstatement of cocaine-seeking.

Morgan H James1, Janine L Charnley, Emily M Levi, Emma Jones, Jiann Wei Yeoh, Doug W Smith, Christopher V Dayas.   

Abstract

Orexinergic signalling is critical to drug relapse-like behaviour; however, the CNS sites(s) of action remain unknown. Two candidate brain regions are the paraventricular thalamus (PVT) and ventral tegmental area (VTA). We assessed the effect of intra-PVT or -VTA administration of the orexin-1 receptor (OrxR1) antagonist SB-334867 on discriminative cue-induced cocaine-seeking. Animals received either PVT- or VTA-directed SB-334867 (0, 3 or 6 μg; 0, 1 or 3 μg, respectively) prior to reinstatement testing elicited by presenting cocaine-paired stimuli (S+). The effect of VTA-directed injections of SB-334867 (0 or 3 μg) on locomotor activity was also assessed. Intra-VTA, but not -PVT, SB-334867 dose-dependently attenuated S+-induced reinstatement (3 μg dose, p<0.01). Intra-VTA SB-334867 had no effect on locomotor activity. We conclude that OrxR1 signalling within the VTA, but not the PVT, mediates cue-induced cocaine-seeking behaviour. We hypothesize that blockade of VTA OrxR1 signalling may reduce nucleus accumbens dopamine in response to drug cue presentation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21447232     DOI: 10.1017/S1461145711000423

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  66 in total

1.  Differential orexin/hypocretin expression in addiction-prone and -resistant rats selectively bred for high (HiS) and low (LoS) saccharin intake.

Authors:  Nathan A Holtz; Natalie E Zlebnik; Marilyn E Carroll
Journal:  Neurosci Lett       Date:  2012-06-02       Impact factor: 3.046

2.  Cocaine potentiates excitatory drive in the perifornical/lateral hypothalamus.

Authors:  Jiann Wei Yeoh; Morgan H James; Phillip Jobling; Jaideep S Bains; Brett A Graham; Christopher V Dayas
Journal:  J Physiol       Date:  2012-05-28       Impact factor: 5.182

Review 3.  Modeling cocaine relapse in rodents: Behavioral considerations and circuit mechanisms.

Authors:  Mitchell R Farrell; Hannah Schoch; Stephen V Mahler
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2018-01-03       Impact factor: 5.067

Review 4.  A Decade of Orexin/Hypocretin and Addiction: Where Are We Now?

Authors:  Morgan H James; Stephen V Mahler; David E Moorman; Gary Aston-Jones
Journal:  Curr Top Behav Neurosci       Date:  2017

Review 5.  Multiple roles for orexin/hypocretin in addiction.

Authors:  Stephen V Mahler; Rachel J Smith; David E Moorman; Gregory C Sartor; Gary Aston-Jones
Journal:  Prog Brain Res       Date:  2012       Impact factor: 2.453

Review 6.  The hypothalamus and the neurobiology of drug seeking.

Authors:  Nathan J Marchant; E Zayra Millan; Gavan P McNally
Journal:  Cell Mol Life Sci       Date:  2011-09-23       Impact factor: 9.261

Review 7.  Orexin/hypocretin based pharmacotherapies for the treatment of addiction: DORA or SORA?

Authors:  Shaun Yon-Seng Khoo; Robyn Mary Brown
Journal:  CNS Drugs       Date:  2014-08       Impact factor: 5.749

8.  Regulation of the ventral tegmental area by the bed nucleus of the stria terminalis is required for expression of cocaine preference.

Authors:  Gregory C Sartor; Gary Aston-Jones
Journal:  Eur J Neurosci       Date:  2012-10-08       Impact factor: 3.386

9.  Attenuation of saccharin-seeking in rats by orexin/hypocretin receptor 1 antagonist.

Authors:  Angie M Cason; Gary Aston-Jones
Journal:  Psychopharmacology (Berl)       Date:  2013-03-15       Impact factor: 4.530

10.  mTORC1 inhibition in the nucleus accumbens 'protects' against the expression of drug seeking and 'relapse' and is associated with reductions in GluA1 AMPAR and CAMKIIα levels.

Authors:  Morgan H James; Rikki K Quinn; Lin Kooi Ong; Emily M Levi; Janine L Charnley; Doug W Smith; Phillip W Dickson; Christopher V Dayas
Journal:  Neuropsychopharmacology       Date:  2014-01-28       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.